Lin Shan

Lin Shan

Auto-generated profile, based on publicly available information

Lin Shan

State Key Laboratory of RNA Innovation, Science and Engineering, New Cornerstone Science Laboratory, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Nature
Verified
Journal Article
Closed access
PDF file
LSLin Shan
Lin Shan
GXGuang Xu
Guang Xu
RYRunwen Yao
Runwen Yao
PLPeng-Fei Luan
Peng-Fei Luan
YHYoukui Huang
Youkui Huang
LCLing-Ling Chen
Ling-Ling Chen

25 April 2022 in BMC Biology
Verified
Journal Article
Open access
PDF file
HHHongxin Huang
Hongxin Huang
GHGuanjie Huang
Guanjie Huang
ZTZhihong Tan
Zhihong Tan
YHYongfei Hu
Yongfei Hu
LSLin Shan
Lin Shan
ZRZhili Rong
Zhili Rong
Background: The CRISPR-Cas12a (formerly Cpf1) system is a versatile gene-editing tool with properties distinct from the broadly used Cas9 system. Features such as recognition of T-rich protospacer-adjacent motif (PAM) and generation of sticky breaks, as well as amenability for multiplex editing in a single crRNA and lower off-target nuclease activity, broaden the targeting scope of available tools and enable more accurate genome editing. However, the widespread use of the nuclease for gene editing, especially in clinical applications, is hindered by insufficient activity and specificity despite previous efforts to improve the system. Currently reported Cas12a variants achieve high activity with a compromise of specificity. Here, we used structure-guided protein engineering to improve both editing efficiency and targeting accuracy of Acidaminococcus sp. Cas12a (AsCas12a) and Lachnospiraceae bacterium Cas12a (LbCas12a). Results: We created new AsCas12a variant termed “AsCas12a-Plus” with increased activity (1.5~2.0-fold improvement) and specificity (reducing off-targets from 29 to 23 and specificity index increased from 92% to 94% with 33 sgRNAs), and this property was retained in multiplex editing and transcriptional activation. When used to disrupt the oncogenic BRAFV600E mutant, AsCas12a-Plus showed less off-target activity while maintaining comparable editing efficiency and BRAFV600E cancer cell killing. By introducing the corresponding substitutions into LbCas12a, we also generated LbCas12a-Plus (activity improved ~1.1-fold and off-targets decreased from 20 to 12 while specificity index increased from 78% to 89% with 15 sgRNAs), suggesting this strategy may be generally applicable across Cas12a orthologs. We compared Cas12a-Plus, other variants described in this study, and the reported enCas12a-HF, enCas12a, and Cas12a-ultra, and found that Cas12a-Plus outperformed other variants with a good balance for enhanced activity and improved specificity. Conclusions: Our discoveries provide alternative AsCas12a and LbCas12a variants with high specificity and activity, which expand the gene-editing toolbox and can be more suitable for clinical applications.

23 July 2025 in Nature
Verified
Journal Article
Closed access
PDF file
YPYu-Hang Pan
Yu-Hang Pan
LSLin Shan
Lin Shan
YZYu-Yao Zhang
Yu-Yao Zhang
ZYZheng-Hu Yang
Zheng-Hu Yang
YZYuan Zhang
Yuan Zhang
LCLing-Ling Chen
Ling-Ling Chen

19 May 2026 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
LSLin Shan
Lin Shan
YSYunsheng Sun
Yunsheng Sun
SWSarah A Woodson
Sarah A Woodson
LCLing-Ling Chen
Ling-Ling Chen

10 August 2026 in Nature
Verified
Journal Article
Open access
PDF file
LSLin Shan
Lin Shan
GXGuang Xu
Guang Xu
RYRunwen Yao
Runwen Yao
PLPeng-Fei Luan
Peng-Fei Luan
YHYoukui Huang
Youkui Huang
LCLing-Ling Chen
Ling-Ling Chen